Anticoagulant treatment and COVID‐19 mortality among older adults living in nursing homes in Sweden

• Published in: Health science reports Vol. 6; no. 11; pp. e1692 - n/a
• Main Authors: Kananen, Laura, Molnár, Christian, Ansker, Fredrik, Kozlowska, Daria Julianna, Hägg, Sara, Jylhävä, Juulia, Religa, Dorota, Raaschou, Pauline
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2023; Wiley
• Subjects: Anticoagulants; cohort studies; COVID-19; Medicin och hälsovetenskap; Mortality; nursing home; Older people; treatment outcome; Sweden; anticoagulants; cohort studies; mortality; nursing home; COVID‐19; treatment outcome
• ISSN: 2398-8835; 2398-8835
• DOI: 10.1002/hsr2.1692

Background Anticoagulants (AC) were introduced in March 2020 as standard of care in nursing home (NH) residents affected with COVID‐19 in the Stockholm region, Sweden. ACs are proven to reduce the risk of complications and mortality from COVID‐19 among patients of other ages and settings, but there is limited scientific evidence underpinning this practice in the NH setting. Methods This matched cohort study included 182 NH residents in the Stockholm Region diagnosed with COVID‐19 in March–May 2020. The main exposure was any AC treatment. Exposed (n = 91), 49% prevalent (pre‐COVID‐19 diagnosis) AC and 51% incident AC were compared with unexposed controls (n = 91). The outcome was 28‐days all‐cause mortality after COVID‐19 infection. The mortality odds ratios (OR) were assessed using logistic regression, adjusted for age, sex, multimorbidity, and mobility, also stratified by incident or prevalent AC‐type, age group, and sex. Results Of the 182 individuals diagnosed with COVID‐19 (median age 88 years, 68% women), 39% died within 28 days after diagnosis. Use of either incident or prevalent AC was associated with a reduced, adjusted 28‐day mortality (OR[95% CI]: 0.31[0.16–0.62]). In stratified analyses, the association was significant in both age groups: 70–89 (OR: 0.37 [0.15–0.89]) and 90–99 years of age (OR: 0.22 [0.07–0.65]. In sex‐stratified analysis, the AC‐lowering effect was significant in women only (OR: 0.28[0.11–0.67]). In the analyses stratified by AC type, the mortality‐lowering effect was observed for both prevalent AC (OR: 0.35[0.12–0.99]) and incident AC (OR: 0.29[0.11–0.76]). Conclusions Both prevalent and incident use of ACs in prophylactic dosing was associated with reduced 28‐day mortality among older individuals with COVID‐19 in a NH setting. The effect was seen across age‐strata and in women. The findings present new insight in best practice for individuals diagnosed with COVID‐19 in the NH setting. Key points Both prevalent use of DOAC and newly initiated LMWH at the time of diagnosis of COVID‐19 was associated with lowered mortality among older individuals living in nursing homes. This effect was significant among females but not males, which may be explained by limited power. The study did not detect any adverse events, but the number of exposed individuals in our study was not sufficient to explore the risk of serious adverse events, such as bleeding.